Bioxcel Therapeutics Stock Performance
| BTAI Stock | USD 0.41 0.04 8.89% |
The firm shows a Beta (market volatility) of 1.87, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioXcel Therapeutics will likely underperform. At this point, BioXcel Therapeutics has a negative expected return of -0.46%. Please make sure to confirm BioXcel Therapeutics' maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if BioXcel Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioXcel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
1 | Disposition of 521 shares by Frank Yocca of BioXcel Therapeutics subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Matthew Wiley of 750 shares of BioXcel Therapeutics subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of 215 shares by Matthew Wiley of BioXcel Therapeutics at 0.6908 subject to Rule 16b-3 | 09/16/2024 |
4 | Mizuho maintains Neutral rating on BioXcel Therapeutics stock - Investing.com | 09/23/2024 |
5 | Disposition of 2610 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3 | 09/26/2024 |
6 | Disposition of 5556 shares by Oneill Vincent of BioXcel Therapeutics at 0.55 subject to Rule 16b-3 | 10/03/2024 |
7 | BioXcel Therapeutics CSO sells shares worth 3,946 | 10/04/2024 |
8 | BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 for Treating Acute Stress Disorder | 10/15/2024 |
9 | BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 | 11/08/2024 |
10 | BioXcel Therapeutics Inc Reports Q3 2024 Earnings Net Revenue at 214K, Net Loss Narrows to 13.7M | 11/14/2024 |
11 | BioXcel Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Trials and ... | 11/15/2024 |
12 | BioXcel Therapeutics amends credit agreement, issues new warrants | 11/21/2024 |
13 | BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering | 11/22/2024 |
| Begin Period Cash Flow | 193.7 M |
BioXcel |
BioXcel Therapeutics Relative Risk vs. Return Landscape
If you would invest 62.00 in BioXcel Therapeutics on September 2, 2024 and sell it today you would lose (21.00) from holding BioXcel Therapeutics or give up 33.87% of portfolio value over 90 days. BioXcel Therapeutics is currently does not generate positive expected returns and assumes 6.2176% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than BioXcel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioXcel Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioXcel Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioXcel Therapeutics, and traders can use it to determine the average amount a BioXcel Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0735
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BTAI |
Estimated Market Risk
| 6.22 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioXcel Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioXcel Therapeutics by adding BioXcel Therapeutics to a well-diversified portfolio.
BioXcel Therapeutics Fundamentals Growth
BioXcel Stock prices reflect investors' perceptions of the future prospects and financial health of BioXcel Therapeutics, and BioXcel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioXcel Stock performance.
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (14.89) % | ||||
| Current Valuation | 84.34 M | ||||
| Shares Outstanding | 48.35 M | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 9.10 X | ||||
| Revenue | 1.38 M | ||||
| Gross Profit | 355 K | ||||
| EBITDA | (165.42 M) | ||||
| Net Income | (179.05 M) | ||||
| Cash And Equivalents | 233.45 M | ||||
| Cash Per Share | 8.33 X | ||||
| Total Debt | 101.38 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 12.25 X | ||||
| Book Value Per Share | (1.89) X | ||||
| Cash Flow From Operations | (155.01 M) | ||||
| Earnings Per Share | (2.04) X | ||||
| Market Capitalization | 21.87 M | ||||
| Total Asset | 73.7 M | ||||
| Retained Earnings | (590.6 M) | ||||
| Working Capital | 44.88 M | ||||
| Current Asset | 609.37 K | ||||
| Current Liabilities | 1.67 M | ||||
About BioXcel Therapeutics Performance
By evaluating BioXcel Therapeutics' fundamental ratios, stakeholders can gain valuable insights into BioXcel Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioXcel Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioXcel Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 576.76 | 547.92 | |
| Return On Tangible Assets | (2.43) | (2.55) | |
| Return On Capital Employed | (3.70) | (3.51) | |
| Return On Assets | (2.43) | (2.55) | |
| Return On Equity | 3.17 | 3.33 |
Things to note about BioXcel Therapeutics performance evaluation
Checking the ongoing alerts about BioXcel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioXcel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioXcel Therapeutics generated a negative expected return over the last 90 days | |
| BioXcel Therapeutics has high historical volatility and very poor performance | |
| BioXcel Therapeutics has some characteristics of a very speculative penny stock | |
| BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 355 K. | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioXcel Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering |
- Analyzing BioXcel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioXcel Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining BioXcel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioXcel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioXcel Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioXcel Therapeutics' stock. These opinions can provide insight into BioXcel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |